Baird Remains Positive on Jounce Therapeutics (JNCE)
Baird lowered its price target on Jounce Therapeutics (NASDAQ: JNCE) to $20.00 (from $35.00) while maintaining a Outperform ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)